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Matriptase is a type II transmembrane serine protease containing two complement 
proteases C1r/C1s–urchin embryonic growth factor–bone morphogenetic protein 
domains (CUB repeat) and four low-density lipoprotein receptor class A domains 
(LDLRA repeat). The single-chain zymogen of matriptase has been found to exhibit 
substantial protease activity, possibly causing its own activation (i.e., conversion to a 
disulfide-linked two-chain fully active form), although the activation appears to be 
mediated predominantly by two-chain molecules. Our aim was to assess the roles of 
CUB and LDLRA repeats in zymogen activation. Transient expression studies of 
soluble truncated constructs of recombinant matriptase in COS-1 cells showed that the 
CUB repeat had an inhibitory effect on zymogen activation, possibly because it 
facilitated the interaction of two-chain molecules with a matriptase inhibitor, hepatocyte 
growth factor activator inhibitor type-1. By contrast, the LDLRA repeat had a 
promoting effect on zymogen activation. The effect of the LDLRA repeat appears to 
reflect its ability to increase zymogen activity. The proteolytic activities were higher in 
pseudozymogen forms of recombinant matriptase containing the LDLRA repeat than in 
a pseudozymogen without the repeat. Our findings provide new insights into the roles of 
these non-catalytic domains in the generation of active matriptase. 
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Matriptase is a member of the type II transmembrane serine protease group, which is 
characterized by the presence of an N-terminal cytoplasmic domain followed by a 
signal anchor transmembrane domain and an extracellular domain, including a 
C-terminal serine protease catalytic domain (Fig. 1) (1–6). Matriptase is first 
synthesized as a zymogen comprising 855 amino acid residues in human, mouse and rat 
enzymes. The matriptase zymogen undergoes cleavage between Arg614 and Val615 
(activation cleavage) and the disulfide-linked two-chain fully active enzyme is 
generated (Fig. 1) (1–6). Two-chain matriptase exhibits activity with trypsin-like 
specificity and can cleave and activate a number of proteins, including pro-hepatocyte 
growth factor (HGF) and the precursor of a membrane-bound serine protease, prostasin 
(7–9). The potential substrates, abundant expression in epithelial cells and in 
keratinocytes and characteristic phenotypes in matriptase gene-disrupted mice, suggest 
that the enzyme plays important roles in the establishment and maintenance of epithelial 




The activation cleavage of matriptase zymogen is believed to occur through a 
mechanism requiring its own catalytic triad (His656, Asp711 and Ser805) (1, 2, 13–15). 
For instance, recombinant (or r-) forms of full-length matriptase, in which any residues 
4 
of the catalytic triad are changed to an alanine residue, are unable to undergo activation 
when expressed exogenously in BT549 breast cancer cells (13). To date, the zymogen 
molecules have been postulated to undergo transactivation by which a zymogen 
interacts with another zymogen, producing the activation cleavage of each zymogen (1, 
13). If so, matriptase zymogen should exert protease activity. We have found that (i) a 
pseudozymogen form of r-matriptase comprising the entire extracellular domain forms a 
catalytic triad analogous to His–Asp–Ser of trypsin-like serine proteases and that (ii) the 
r-pseudozymogen effectively hydrolyses a peptide substrate, acetyl-L-Lys–L-Thr–L- 
Lys–L-Gln–L-Leu–L-Arg–4-methyl-coumaryl-7-amide (hereinafter abbreviated as Ac- 
KTKQLR-MCA), whose sequence shares some sequence similarities with the 
activation-cleavage site of this protease (Fig. 1) (16). In addition, the r-pseudozymogen 
exhibited optimal Ac-KTKQLR-MCA-hydrolysing activity under mildly acidic and low 
ionic strength conditions (e.g., 5 mM NaCl and pH 6.0), under which matriptase 
zymogen endogenously expressed in a human mammary epithelial line 184 A1N4 
undergoes activation with optimal efficiency (17–19). Our findings reinforce the 
concepts that the zymogen molecules can activate themselves by self-catalysed 
proteolysis and thus that this protease serves as an initiator molecule of a protease 
cascade that is involved in the maintenance of epithelial and epidermal integrity (1, 3). 
It should be noted, however, that the zymogen activation seems to be mediated 
predominantly by two-chain molecules. Indeed, the Ac-KTKQLR-MCA- hydrolysing 
activity was higher for the corresponding two-chain r-matriptase than for the 
r-pseudozymogen (16). 
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Matriptase has an extracellular non-catalytic stem domain comprising a sea urchin 
sperm protein–enteropeptidase–agrin (SEA) domain, followed by two tandem repeats of 
complement proteases C1r/C1s–urchin embryonic growth factor–bone morphogenetic 
protein (CUB) domain and four tandem repeats of a low-density lipoprotein receptor 
class A (LDLRA) domain (Fig. 1) (1–6). Lin and co-workers have proposed the 
intimate involvement of the matriptase stem domain in its zymogen activation (13, 19). 
For instance, a site-directed mutant of full-length matriptase (Gly149Asn), which was 
designed to escape post-translational cleavage between Gly149 and Ser150 within the 
SEA domain (refer to Fig. 1), was unable to undergo activation (13). A possible 
explanation for this is that, upon cleavage within the SEA domain, the matriptase 
zymogen undergoes a conformational change or reorientation on the membrane surface 
that makes the protease susceptible to activation cleavage. The CUB and LDLRA 
repeats were also shown to affect the zymogen activation (13, 19). However, the 
definitive roles of these repeats in the zymogen activation remain unclear. We have 
shown that (i) the matriptase second CUB domain (CUB domain II) serves as an 
additional site for interaction with a physiological inhibitor of this protease, HGF 
activator inhibitor type-1 (HAI-1), which contains two protease-inhibitory Kunitz 
domains, and that (ii) the interaction between CUB domain II and HAI-1 facilitates the 
primary inhibitory interaction between the enzyme and inhibitor (i.e., interaction 
between the SPCD of two-chain matriptase and the first Kunitz domain) (Fig. 1) (20). 
This finding raises the possibility that CUB domain II may suppress zymogen activation 
by accelerating the rate of inhibition of the two-chain matriptase by HAI-1. 
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The purpose of the present study was to gain insights into the role(s) of CUB and 
LDLRA repeats in the activation of matriptase zymogen. To date, structural 
requirements of matriptase zymogen for its activation cleavage have been studied upon 
transient expression of the membrane-bound forms of r-matriptase in cultured cells 
(13–15, 21, 22). In the context of membrane-bound forms, internal deletions and point 
mutations showed differential effects on the activation cleavage (13). For example, 
full-length r-matriptase bearing a mutation in its LDLRA repeat (tyrosine replacement 
of aspartic acid residues comprising the calcium cage in each domain) rarely underwent 
activation, whereas a truncated variant lacking the repeat did it to a similar extent as in 
full-length, wild-type (WT) r-matriptase (13). Expression studies using soluble, 
truncated forms of r-matriptase could be expected to solve contradictory conclusions 
regarding the roles of internal domains (CUB and LDLRA repeats). In addition, the 
activation behaviors of soluble variants in cellulo would provide a coherent 
interpretation of the in vitro results obtained using soluble, truncated, pseudozymogen 
forms of r-matriptase (pro-CLS-, pro-LS- and pro-S-mat
EK-A 
variants, Fig. 1) (20). For 
these reasons, we prepared plasmids for the expression of secreted variants of 
r-matriptase and investigated whether the r-matriptase variants undergo activation 
cleavage when expressed in COS-1 monkey kidney cells. Our in cellulo results provided 
suggestive evidence that the CUB repeat had an inhibitory effect, whereas the LDLRA 
repeat had a promoting effect, on zymogen activation. In vitro experiments using the 
pseudozymogen forms of r-matriptase showed that the LDLRA repeat increased the 
protease activity of matriptase zymogen. To our knowledge, this is the first report 
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showing how CUB and LDLRA repeats of matriptase participate in its zymogen 
activation. 
 
MATERIALS AND METHODS 
 
Expression Constructs – Plasmids for the expression of pseudozymogen forms of 





 (Cys453–Val855) and pSec-pro-S-matEK-A (Asp603–Val855)] and 
of two secreted variants of r-HAI-1 [designated in this study as pSec-HAI-1
NIK1LK2
 
(Pro41–Ser441) and pSec-HAI-1IK1L (Thr154–Ser370)] have already been constructed 
using pSecTag2/HygroB vector (Invitrogen, Carlsbad, CA) (20, 23). 
The plasmid for the expression of a secreted variant of r-matriptase comprising 
amino acids Gln210–Val855 was created as follows. A DNA fragment was amplified by 
polymerase chain reaction (PCR) with KOD-plus-DNA polymerase (Toyobo, Osaka, 
Japan), 5-TCAGGACAACAGCTGCA-3 and 5-CTATACCCCAGTTTGCTCT-3 as 
the forward and reverse primers, respectively, and a plasmid for the expression of 
full-length, WT rat matriptase (pcDNA-WT-matriptase) (15, 22) as the template. The 
PCR product was phosphorylated with T4 polynucleotide kinase and ligated into the 
SmaI-linearized pT7blue2 vector (Novagen) (pT7-pro-CLS-mat). pT7-pro-CLS-mat 
was digested with KpnI and BamHI, and the resulting fragment was ligated into 
pSec-pro-CLS-mat
EK-A 
from which a fragment produced by digestion with KpnI and 




Plasmids for the expression of secreted variants of r-matriptase comprising amino acids 
Cys453–Val855 and Asp603–Val855 were made using the same method except that 
5-ATGCCCAGGGATGTTCAT-3 and 5-TGACTGTGGGCTGCGATCCTTTAC-3, 












) were created by the same methods as 







, except that a plasmid for the expression of a full-length variant of 
r-matriptase bearing an alanine instead of serine at position 805 (pcDNA- 
S805A/matriptase) (15) was used as the template in the PCR. The sequences of the 
expression plasmids constructed in the present study were determined in both directions 
using the dideoxynucleotide chain-termination method, as described previously (5). 
 
Transfection of Expression Plasmids into COS-1 Cells and Sample Preparation – The 
procedure for the transfection of constructs into COS-1 cells using 
Lipofectamine2000™ (Invitrogen) has been described previously (15, 21). Note that 
each of the six plasmids for the expression of r-matriptase variants (2.4 g) was 
co-transfected with pSecTag2/hygroB (2.4 g) or pSec-HAI-1NIK1LK2 (2.4 g). Cells 
were incubated for 24 h after transfection. The transfected cells were then washed three 
times with phosphate-buffered saline (PBS) [8 mM Na2HPO4, 1.5 mM KH2PO4, 136 
mM NaCl and 2.7 mM KCl (pH 7.4)] and then cultured for an additional 24 h in 1 ml of 
serum-free medium. After incubation, the conditioned medium was harvested and 
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transferred to a 1.5 ml microcentrifuge tube in which 100 l of the protease inhibitor 
cocktail Complete™ (1  concentrate) (Roche Diagnostics, Mannheim, Germany) was 
included. After centrifugation at 3,000 g for 5 min at 22C, the resulting supernatant 
was concentrated to 40 l by ultrafiltration using Microcon-10 (10,000 NMWL, 
Millipore, Bedford, MA). After the addition of 10 l of 5  Laemmli protein sample 
buffer (Laemmli buffer) [1  Laemmli buffer, 0.05 M Tris-HCl (pH6.8), 10% glycerol, 
2% sodium dodecylsulfate (SDS) and 0.005% Bromophenol Blue with dithiothreitol at 
a final concentration of 12 mM] (24), the ultrafiltrates were stored at –20C until use. 
 
Analysis of Expression Products of r-Matriptase and r-HAI-1 Variants by 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Blotting – Samples 
were thawed, heated to 95C for 3 min, and subjected to SDS-PAGE (12% 
polyacrylamide). A 20-l portion of the samples was loaded into each lane. After 
separation, the proteins were transferred by electroblotting onto a polyvinylidene 
fluoride membrane (Fluorotrans W; Nihon Genetics, Tokyo, Japan), and the blots were 
rinsed twice with a buffer [50 mM Tris–HCl, (pH 7.5) containing 145 mM NaCl and 
0.1% Tween 20] (hereinafter called TBST). The blots were blocked by incubation in 
TBST containing 2% Difco™ skim milk (Becton, Dickinson and Company, Franklin 
Lakes, NJ) for 18 h at 4C. The signals for r-matriptase variants were visualized as 
follows. After rinsing with TBST, the blots were incubated with a rabbit anti-matriptase 
SPCD antibody (Spr992) (22) diluted in an immunoreaction- enhancer solution (Can 
Get Signal
®
 Solution I, Toyobo) (1:20 dilution) for 18 h at 22C. After washing with 
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TBST, the blots were incubated with a goat anti-rabbit IgG secondary antibody 
conjugated with horseradish peroxidase (HRP; Dako Japan, Kyoto, Japan) diluted in 
another immunoreaction-enhancer solution (Can Get Signal
®
 Solution II, Toyobo) 
(1:3,000 dilution) for 2 h at 22C. The blots were washed with TBST, and the protein 
bands were visualized using an ECL
®
 detection system (GE Healthcare, Tokyo, Japan). 
The r-HAI-1 variant and the non-activated forms of r-matriptase variants were probed 
using HRP-conjugated S-protein (hereinafter called S-protein–HRP) (Novagen, 
Madison, WI) diluted in Can Get Signal
®
 Solution II (1:3,000 dilution). 
 
Preparation of Pseudozymogen Forms of r-Matriptase and HAI-1
IK1L
 – We have 







(20). In the present study, we established a 
CHO-K1 cell line expressing HAI-1
IK1L
 using the same method as described previously 
(23). 
The stably transfected cells were cultured in a 75 cm
2
 plastic flask (Asahi Techno 
Glass) as described previously (23). After reaching confluence, cells were washed three 
times with PBS, and 10 ml of Ham’s F12 without foetal bovine serum was added to the 
flask. After 48 h of incubation, the conditioned medium was collected, and fresh 
serum-free medium was added. This was repeated until half of the cells had peeled off. 
The collected media were centrifuged immediately at 3,000 g for 10 min at 22C, and 
the resulting supernatants were stored at –20C until use. For purification, 300 ml of the 
conditioned media was collected into three flasks. After thawing, the media were pooled 
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and concentrated to 2.5 ml by ultrafiltration using an Amicon
®
 Ultra-15 membrane filter 
(50,000 MWCO for pro-CLS-mat
EK-A





, and 10,000 MWCO for pro-S-mat
EK-A
, Millipore). The concentrated medium 
was subjected to gel filtration in a buffer [25 mM HEPES (pH 7.5) containing 145 mM 
NaCl and 0.1% Triton X-100] (hereinafter called purification buffer) using a PD-10 
column (GE Healthcare) with an elution volume of 3.5 ml. The gel filtrate was divided 
equally, and each part was transferred to a 2.0-ml microcentrifuge tube in which a 
62.5-l slurry of immobilized S-protein was included. The tubes were incubated for 30 
min at 22C with rocking. After brief centrifugation, the supernatants were incubated 
again with immobilized S-protein as described above. The precipitated slurries were 
pooled (250 l) and washed three times with 1.5 ml of purification buffer and twice 
with 1.5 ml of 10 mM HEPES (pH 7.5) containing 5 mM NaCl and 0.01% Triton X-100 
(hereinafter called elution buffer). To elute these r-matriptase molecules, the washed 
slurry was transferred with 500 l of elution buffer containing 200 M of synthetic 
S-Tag peptide (KETAAAKFERQHIDS, synthesized by BEX, Tokyo, Japan) to a spin 
column (Attoprep™, 0.22-m pore size, Atto, Tokyo, Japan) and centrifuged at 5,000 g 
for 1 min at 22C. The eluate was subjected to gel filtration in elution buffer using an 
NAP-5 column (GE Healthcare) with an elution volume of 1.0 ml and stored at –20C 
until use. 
The concentration of each r-matriptase variant was measured semi-quantitatively 
as follows. Various amounts of r-matriptase variants and HAI-1
IK1L
 and Perfect Protein 
Marker™ protein size marker (Novagen), in which each protein was fused to an S-Tag 
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and the concentration of each marker was known, were subjected to reducing 
SDS-PAGE (12% polyacrylamide) followed by Western transfer. The blots were probed 
with S-protein–HRP. The X-ray films were scanned digitally, and the signal intensities 
of protein bands were analysed by densitometry as described previously (23). The 
concentrations of each r-matriptase variant and HAI-1
IK1L
 were calculated by comparing 
the signal density of each band of interest with the 50-kDa protein contained as the 
protein marker. 
 
Preparation of r-Matriptase Variants Corresponding to the Two-Chain Form and 
Determination of Their Ac-KTKQLR-MCA-Hydrolysing Activities – To generate 
r-matriptase variants corresponding to the two-chain form of matriptase (hereinafter 







was incubated for 24 h at 
22C with a recombinant form of enteropeptidase (hereinafter called r-EK) (Novagen). 
The final concentration of r-EK was 1 unit/ml. After incubation, the solution (activation 
mixture) was stored at –20C until use. The concentrations of CLS-mat, LS-mat and 
S-mat in the activation mixture were evaluated by reducing SDS-PAGE (12% 
polyacrylamide) and Western blotting using Spr992 (22). The signal density of a 28-kDa 
band produced from the SPCD part of CLS-mat, LS-mat or S-mat was compared with 
that of a 90-kDa band produced from pro-CLS-mat
EK-A
, whose concentration had been 
determined as described above. 
Ac-KTKQLR–MCA (Peptide Institute, Osaka, Japan) was dissolved in dimethyl 
13 
sulfoxide at a concentration of 20 mM and stored at –20C until use. A portion of 
CLS-mat, LS-mat or S-mat was incubated with 1 mM of Ac-KTKQLR-MCA in 25 mM 
HEPES buffer (pH 7.5) containing 145 mM NaCl and 0.1% Triton X-100 (hereinafter 
called HEPES buffer) for 10 min at 37C in a volume of 80 l. The reaction was 
terminated by adding 350 l of 0.1 M monochloroacetic acid in 0.1 M sodium acetate 
buffer, pH 4.3 (stop solution), and the absorbance at 370 nm was measured. The initial 














and Determination of the Kinetic Parameters for the Hydrolysis – Incubations were 
performed at 37C in a 0.5-ml microcentrifuge tube. The reactions were initiated by the 
addition of 10 l of elution buffer containing one of the pseudozymogens (3.2 nM for 
the pro-CLS- and pro-LS-mat
EK-A
 variants; 16 nM for the pro-S-mat
EK-A
 variant) or the 
buffer alone to 10 l of buffer [200 mM MES-NaOH (pH 6.0) buffer with 10 mM NaCl 
and 0.02% Triton X-100] containing 0.1 nM HAI-1
IK1L
 and Ac-KTKQLR-MCA. The 
final concentrations of the substrate were 0, 1.95, 3.9, 7.8, 15.6, 31.3, 62.5 and 125 M. 
The reaction mixtures containing the pseudozymogen forms of r-matriptase variants 
were incubated for 72 h. To prevent water evaporation within the tube, the incubation 
was conducted using a temperature controller (PC805-MI, ASTEC, Fukuoka, Japan). 
The reactions were terminated by adding 400 l of stop solution. One hundred- 
microlitre aliquots of the final reaction mixtures were added to the wells of a 96-well 
14 
assay plate, and the fluorescence of 4-methyl-coumaryl-7-amine liberated from 
Ac-KTKQLR-MCA was measured using a plate reader (PowerScan, Dainippon 
Sumitomo Pharma, Osaka, Japan) at an excitation wavelength of 380 nm and an 
emission wavelength of 460 nm. The concentration of the product was assessed by 
comparing the fluorescence value with that of stop solution containing 4-methyl- 
coumaryl-7-amine at various concentrations. To determine the enzyme-catalysed 
reaction rate, the non-enzymatic spontaneous reaction rate of the absorbance increase 
was subtracted from the reaction rate observed in the presence of the enzyme. The 
Michaelis constant (Km) and the rate of maximum turnover (kcat) for the hydrolysis of 
Ac-KTKQLR-MCA were calculated by fitting the rate data to the Michaelis–Menten 




Identification of Secreted Variants of r-Matriptase and the Detection Methods – To 
assess the roles of CUB and LDLRA repeats in the activation of matriptase zymogen by 
in cellulo experiments, we prepared plasmids for the expression of secreted variants of 
r-matriptase: pro-CLS-mat
WT
 comprising the CUB and LDLRA repeats and the SPCD; 
pro-LS-mat
WT
 comprising the LDLRA repeat and SPCD; and pro-S-mat
WT
 comprising 
only the SPCD (Fig. 1). The superscript WT in these r-matriptase variants reflects that 
each of them has both the activation-cleavage site and the catalytic triad, identical to 
full-length, WT rat matriptase. In the present study, the expression plasmids for their 
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respective active-site mutants (i.e., mutant in which a serine residue corresponding to 







, were also prepared (Fig. 1). 
The co-transfection of cDNAs encoding HAI-1 has been shown to be required for 
successful detection of full-length, WT r-matriptase in transient expression experiments 
with cultured cells, including COS-1 cells (13, 15, 21, 22). In the absence of HAI-1, the 
r-matriptase inadvertently activated in the intracellular environment appears to undergo 
extensive degradation via a self-catalysed mechanism, thus being rarely detectable (21). 
Upon co-expression with HAI-1, both zymogen and two-chain forms of the r-matriptase 
were detectable (13, 15, 21, 22). It is also noted upon co-expression with HAI-1 in 
COS-1 cells that (i) the activation cleavage of the r-matriptase can occur on the surface 
of cells and that (ii) both the non-activated and activated forms of r-matriptase 
frequently undergo ectodomain shedding, thereby being detected predominantly in the 
conditioned medium (15, 21, 22). In the present study, we transfected the plasmids to 
induce the expression of secreted variants of r-matriptase into the cells with or without a 
plasmid for the expression of a secreted variant of r-HAI-1 comprising all of the 
extracellular domain (pSec-HAI-1
NIK1LK2
, Fig. 1) (21, 23) and investigated whether the 
r-matriptase variants undergoing activation cleavage (i.e., cleavage after an arginine 
residue corresponding to matriptase Arg614) can be detected in media conditioned by 
transfected cells. The occurrence of activation cleavage was assessed to determine 
whether a 28-kDa protein is immunostained on a Western blot with an anti-matriptase 
SPCD antibody (Spr992) following reducing SDS-PAGE (refer to Fig. 1) (21, 22). The 
16 
r-matriptase variants that did not undergo cleavage after an arginine residue 
corresponding to matriptase Arg614 were analysed by reducing SDS-PAGE and 
Western blotting with Spr992 or with S-protein–HRP (note that an S-Tag is fused to the 
N-terminus of each variant). HAI-1
NIK1LK2
 has been detected as a 59-kDa band by 
reducing SDS-PAGE and Western blotting with S-protein–HRP (21). 
 
Analysis of the Expression of pro-CLS-mat
WT
 and its Respective Active-site Mutant – 




 (Fig. 2). 
When a sample of media conditioned by COS-1 cells transfected with 
pSec-pro-CLS-mat
WT
 alone was probed with Spr992, no signal at the position 
corresponding to 28 kDa was produced (left panel, lane CLS-WT). A similar result was 





 (left panel, lane CLS-WT + HAI-1). Using Spr992 as a probe, 
several protein bands were produced from medium samples of transfected cells 
(especially dense at the 80- to 90-kDa positions; also refer to the data for COS-1 cells 
transfected with pSecTag2/HygroB vector alone shown in Supplementary Fig. S1, lane 
Mock). These signals are derived from unknown proteins secreted by COS-1 cells (21). 
When probed with S-protein–HRP, the medium sample of cells transfected with 
pSec-pro-CLS-mat
WT
 alone produced no visible bands (right panel, lane CLS-WT). In 
the medium sample of cells co-transfected with pSec-HAI-1
NIK1LK2
, a protein band at 
the 90-kDa position, indicative of the pro-CLS-mat
WT
 variant, was produced (right 











 suggest that the activation cleavage of 
pro-CLS-mat
WT
 occurs rarely or not at all. 
Irrespective of co-transfection of pSec-HAI-1
NIK1LK2
, the samples of media 
conditioned by cells transfected with pSec-pro-CLS-mat
S805A
 produced a signal at the 
90-kDa position in a Western blot probed by S-protein–HRP (right panel, lanes 
CLS-S805A and CLS-S805A + HAI-1). The 90-kDa band may represent 
pro-CLS-mat
S805A





 could not be evaluated in a Western blot probed with Spr992 
because of the dense signals for unknown proteins around the position (left panel). 
 
(Fig. 2 and Supplementary Fig. S1) 
 
Analysis of the Expression of pro-LS-mat
WT
 and its Respective Active-site Mutant – We 




 (Fig. 3). When a 
sample of media conditioned by cells transfected with pSec-pro-LS-mat
WT
 alone was 
probed with Spr992, no signal at the 28-kDa position was detected (left panel, lane 
LS-WT). A protein band at the 28-kDa position was visualized clearly in medium 




 (left panel, 
lane LS-WT + HAI-1), demonstrating that the pro-LS-mat
WT
 variant undergoes 







and a trace of the 
18 
57-kDa band representing pro-LS-mat
WT
 (right panel, lane LS-WT + HAI-1). In the 
sample of cells transfected with pSec-pro-LS-mat
WT
 alone, no apparent protein bands 
were visualized (right panel, lane LS-WT). 
When probed with Spr992, a protein band at the position corresponding to 57 kDa 
was visualized in samples of cells transfected with pSec-pro-LS-mat
S805A
 alone and in 





panel, lanes LS-S805A and LS-S805A + HAI-1). Similarly, the 57-kDa band was also 
visualized when probed with S-protein–HRP (right panel, lanes LS-S805A and 
LS-S805A + HAI-1). The results obtained using cells transfected with pSec-pro-LS- 
mat
S805A
 indicated that pro-LS-mat
WT
 underwent activation cleavage via a mechanism 




Analysis of the Expression of pro-S-mat
WT
 and its Respective Active-site Mutant – We 




 in Fig. 4. When 
the sample of media conditioned by cells transfected with pSec-pro-S-mat
WT
 alone was 
probed with Spr992, no signal at the 28-kDa position was detected (left panel, lane 
S-WT), although protein bands at the 40-, 36- and 31-kDa positions were visualized. A 





 (left panel, lane S-WT and HAI-1), 
indicating that the pro-S-mat
WT
 variant undergoes activation cleavage. The 40-, 36- and 
19 
31-kDa bands were also visualized in the same lane. Irrespective of the co-transfection 
with pSec-HAI-1
NIK1LK2
, the samples of media conditioned by cells transfected with 
pSec-pro-S-mat
WT
 produced 40-, 36- and 31-kDa bands in a Western blot probed with 
S-protein–HRP (right panel, lanes S-WT and S-WT and HAI-1). Judging from the 
molecular masses, the three bands may represent pro-S-mat
WT 
species. We also note that 
the appearance of the three pro-S-mat
WT
 species may be explained by cleavage by 
signal peptidases of COS-1 cells at different sites. 
When probed with Spr992 or S-protein–HRP, 40-, 36- and 31-kDa bands were 
visualized in samples of cells transfected with pSec-pro-LS-mat
S805A
 alone and in 





right panels, lanes S-S805A and S-805A + HAI-1). The appearance of the three 
pro-S-mat
S805A
 species indicates that the active-site mutant also undergoes cleavage by 
signal peptidases of COS-1 cells at different sites. The results obtained using cells 
transfected with pSec-pro-S-mat
S805A
 indicate that the pro-S-mat
WT 
variant undergoes 




Comparison of the Degrees of Activation and Levels of Expression of pro-CLS-, pro-LS- 
and pro-S-mat
WT
 Variants – The degrees of activation cleavage and levels of expression 
of pro-CLS-, pro-LS- and pro-S-mat
WT
 variants were analysed in a Western blot 
(Supplementary Fig. S1). We could not successfully evaluate the levels of expression of 
20 
r-matriptase variants when each of them was expressed alone. Upon co-expression with 
HAI-1
NIK1LK2
, it is evident that the level of expression of pro-S-mat
WT
 was greater than 
that of pro-LS-mat
WT
. In addition, the level of expression of pro-CLS-mat
WT
 was not 
significantly lower than that of pro-LS-mat
WT
. Therefore, it seems unlikely that the level 
of expression seriously affects the activation frequency at least in experiments with 
COS-1 cells. In addition, the levels of HAI-1
NIK1LK2
 detected did not differ substantially 
irrespective of the type of r-matriptase variants
 
co-expressed, suggesting that interaction 
frequencies of the variants with the r-HAI-1 do not differ substantially. 
 
Hydrolysis of Ac-KTKQLR-MCA by Pseudozymogen Forms of r-Matriptase – We have 
produced pseudozymogen forms of r-matriptase using CHO-K1 cells as the host for 
expression (20, 23). Of these, a variant comprising all of the extracellular domain was 
found to exhibit substantial Ac-KTKQLR-MCA-hydrolysing activity (16). In the 
present study, we investigated the Ac-KTKQLR-MCA-hydrolysing activities of the 
pro-CLS-, pro-LS- and pro-S-mat
EK-A
 variants (Fig. 1). Five amino acid residues needed 
for activation cleavage of this protease (Thr–Lys–Gln–Ala–Arg614) were changed to 
those suitable for cleavage by enteropeptidase (Asp–Asp–Asp–Asp–Lys) in any of the 
variants. This allowed for in vitro generation of an N-terminal valine residue 
corresponding to matriptase Val615 by treatment with r-EK (20, 23). Each of the 
r-matriptase variants after treatment with r-EK (CLS-mat, LS-mat and S-mat) 
hydrolysed Ac-KTKQLR-MCA with a reaction rate of about 2 nM s
–1
. This is consistent 
with the observation that the stem domain of matriptase in the two-chain form has no 
21 
substantial effect on the hydrolysis of peptidyl-MCA substrates (25, 26). The pro-CLS-, 
pro-LS- and pro-S-mat
EK-A
 variants not treated with r-EK can be used as models for 
matriptase zymogen. 
In the present study, we prepared a secreted variant of r-HAI-1 comprising the 
internal, first Kunitz and LDLRA domains using CHO-K1 cells (HAI-1
IK1L
, Fig. 1). 
This r-HAI-1 variant was found to be most effective at inhibiting a two-chain 
r-matriptase variant (23). To avoid the detection of activities derived from CLS-mat, 
LS-mat and S-mat occurring inadvertently during incubation, the HAI-1
IK1L
 variant was 
included in the reaction mixtures. We confirmed that the HAI-1
IK1L
 produced in 
CHO-K1 cells exhibited a matriptase-inhibition activity similar to the variant produced 
in COS-1 cells (23). 
The pro-CLS-, pro-LS- and pro-S-mat
EK-A
 variants hydrolysed Ac-KTKQLR- 
MCA. The kcat, Km and kcat/Km values are shown in Table 1. We note that the kcat/Km 
values of the pro-CLS- and pro-LS-mat
EK-A
 variants were similar but more than 10 
times higher than that of the pro-S-mat
EK-A
 variant. These results suggest that the CUB 
repeat has no substantial effect on the expression of zymogen activity and that the 







The CUB domain is a widely occurring module in proteolytic enzymes or proteins that 
are involved in developmental processes, and the domains in certain proteases appear to 
be essential for recognition of natural substrates (27, 28). In matriptase, the second CUB 
domain has been postulated to serve as an additional site for interaction with HAI-1 to 
downregulate its own catalytic activity (20). r-Matriptase variants with the second CUB 
domain (e.g., CLS-mat) are inhibited by HAI-1
NIK1LK2
 with high efficiency, whereas 
those without the domain (e.g., LS-mat and S-mat) are inhibited with low efficiency 
(20). In our transient expression experiments, a protein band at the 28-kDa position was 















) undergoes frequent inactivation by HAI-1
NIK1LK2
, and 
thus the activation cleavage of pro-CLS-mat
WT
 by two-chain pro-CLS-mat
WT
 occurs 
rarely. By contrast, the activated pro-LS-mat
WT
 (hereinafter called two-chain 
pro-LS-mat
WT
) is inactivated rarely by the r-HAI-1 variant, and thus the activation 
cleavage of pro-LS-mat
WT
 by two-chain pro-LS-mat
WT
 occurs efficiently. 
It seems likely that the pro-CLS-mat
WT
 variant exerts protease activity to generate 
two-chain pro-CLS-mat
WT
. This is supported by the observations that (i) the sample of 
cells transfected with pSec-CLS-mat
WT
 alone rarely produced a protein band at the 
90-kDa position, whereas that of cells transfected with pSec-CLS-mat
S805A
 alone did 
and that (ii) pro-CLS-mat
EK-A
 hydrolysed Ac-KTKQLR-MCA to a comparable extent as 
did pro-LS-mat
EK-A




in the intracellular environment might degrade pro-CLS-mat
WT
 and two-chain 
pro-CLS-mat
WT
 progressively, and thus both species would be rarely detected. A similar 
phenomenon may occur in the cells transfected with pSec-LS-mat
WT
 alone and in those 
transfected with pSec-S-mat
WT
 alone. Yet, it is uncertain why an activated form of 
matriptase was detected from medium samples of COS-1 cells transfected with a 
plasmid for expression of full-length, WT r-matriptase and pSec-HAI-1
NIK1LK2
 (21) but 





possible explanation is that the CUB domain-accelerated interaction with the r-HAI-1 
occurs slowly and inefficiently in a cell membrane-associated state of two-chain 
matriptase, whereas it does rapidly and efficiently in the soluble state. 
The LDLRA domain is about 40 amino acids, is biologically ubiquitous, and is 
found in several proteins. In general, this domain is thought to be involved in 
protein–protein interaction (29). In the present study, we found that Ac-KTKQLR- 
MCA-hydrolysing activity was higher in pro-LS-mat
EK-A
 than in pro-S-mat
EK-A
. This 
strongly suggests that one of the important roles of the LDLRA repeat of matriptase is 
to increase the zymogen activity, thereby facilitating the zymogen-catalysed activation 
cleavage of zymogen. Our transient expression experiments also support this idea. The 
pro-S-mat
WT





was rarely detected in the sample from 
cells transfected with pSec-pro-LS-mat
WT 










, whereas the pro-LS-mat
WT
 was hardly 
24 





. In other words, the vast majority of pro-LS-mat
WT 
underwent 
activation cleavage, whereas less than half of pro-S-mat
WT
 did. 
The LDLRA domain of matriptase has been modelled based on the structure of 
the fifth LDL-binding domain of the LDL receptor (30, 31). Interestingly, the fourth 
LDLRA domain of matriptase was predicted to interact with the surface of its SPCD 
opposite to the active-site cleft (30). In addition, matriptase zymogen appears to form a 
catalytic triad analogous to mature trypsin-like serine proteases (16, 32). It is tempting 
to speculate that the putative intramolecular interaction between the LDLRA repeat and 
SPCD within a matriptase zymogen facilitates the conformational change required for 
forming mature form-like structure. The CUB repeat does not appear to exert a 
substantial effect on the expression of zymogen activity. The Ac-KTKQLR-MCA- 






In summary, we have provided insights into the roles of CUB and LDLRA repeats 
of matriptase in its zymogen activation. The CUB repeat might facilitate interaction of 
its SPCD of the two-chain enzyme with HAI-1, thereby contributing to the suppression 
of the activation cleavage of zymogen catalysed by the active enzyme. The LDLRA 
repeat appears to have a critical effect on the expression of zymogen activity. These 
non-catalytic domains of matriptase might be organized in ways that allow this protease 
to serve as the most upstream regulator of the protease cascade that controls epithelial 
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Fig. 1. Schematic illustration of the structures of full-length rat matriptase and 
HAI-1, and their expression constructs. (A) Schematic illustration of the domain 
structures of full-length rat matriptase (Matriptase zymogen). The amino acid 
numbering starts from the putative N-terminus of the protein. The amino- and 
carboxyl-termini are indicated by NH2 and COOH, respectively. The association of the 
amino-terminal part (Met1–Gly149) with the carboxyl-terminal part (Ser150–Val855) is 
illustrated with broken lines. The amino acid sequence around the matriptase 
activation-cleavage site is indicated by the single-letter code with amino acid number at 
the N-terminal valine residue of the SPCD (Val615). The activation-cleavage site is 
indicated by the arrowhead. When cleaved, disulfide-linked two-chain matriptase is 
generated, shown here as “Two-chain matriptase (fully active)”. The SPCD of the 
two-chain matriptase is underlined at the position at which the domain migrates on 
reducing SDS-PAGE (28 kDa). (B) Schematic illustration of the domain structures of 
secreted variants of r-matriptase. The expression vector used (pSecTag2/HygroB) 
contains the sequence of the immunoglobulin  signal peptide allowing for secretion of 
translation products from mammalian cells. All variants were fused to the S-Tag at their 
N-termini. Enterokinase recognition sequences (DDDDK, underlined) and their 





In (A) and (B), the predicted disulfide linkages between two cysteine residues 
corresponding to Cys604 and Cys731 in full-length matriptase and r-matriptase variants 
32 
are shown as –C–C–, and the catalytic triad, His656, Asp711 and Ser805, are indicated 
as H, D and S, respectively, in the SPCD except for the pro-CLS-, pro-LS- and 
pro-S-mat
S805A
 variants, in which a serine residue corresponding to matriptase Ser805 is 
replaced with an alanine residue (denoted by the grey A). TM, transmembrane domain; 
SEA, SEA domain; C1 and C2, CUB domains I and II; L1-4, LDLRA repeat. (C) 
Schematic illustration of the domain structures of full-length rat HAI-1 and secreted 
variants of r-HAI-1. The structure of HAI-1 [HAI-1 (full-length form)] is indicated on 





 are secreted variants of r-HAI-1. S-tag and 
Myc-hexahistidine tag (MH-tag) are fused at their N- and C-termini, respectively. N, 
N-terminal domain; I, internal domain; KD1, Kunitz domain I; L, LDLRA domain; 
KD2, Kunitz domain II; TM, transmembrane domain. 
 












 (CLS-WT + HAI-1), pSec- 
pro-CLS-mat
S805A
 alone (CLS-S805A), and pSec-pro-CLS-mat
S805A
 and pSec- 
HAI-1
NIK1LK2 
(CLS-S805A + HAI-1) were subjected to reducing SDS-PAGE. After 





 migrated is indicated as “Proforms” 
to the right of the right panel. The position to which HAI-1
NIK1LK2 
migrated is indicated 
to the right of the right panel.  The molecular masses of the marker proteins are 
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indicated in kilodaltons (kDa) to the left of the left panel. 
 





Medium samples of COS-1 cells transfected with pSec-pro-LS-mat
WT





 (LS-WT + HAI-1), pSec-pro-LS-mat
S805A
 





HAI-1) were subjected to reducing SDS-PAGE. After Western transfer, the blot was 
probed with Spr992 or S-protein–HRP. The 28-kDa position to which the SPCD part of 
two-chain pro-LS-mat
WT migrated is indicated as “SPCD of two-chain pro-LS-matWT” 
to the right of the left panel. The 57-kDa position at which pro-LS-mat
S805A 
migrated is 





migrated is indicated as “Proforms” to the 
right of the right panel. The position to which HAI-1
NIK1LK2 
migrated is indicated to the 
right of the right panel. The molecular masses of the marker proteins are indicated in 
kilodaltons (kDa) to the left of both panels. 
 





Medium samples of COS-1 cells transfected with pSec-pro-S-mat
WT












(S-S805A + HAI-1) were 
subjected to reducing SDS-PAGE. After Western transfer, the blot was probed with 




 migrated is indicated as “SPCD of two-chain pro-S-matWT” to the right of 






 migrated are indicated as “Proforms” to the right of the left and 
right panels. The position to which HAI-1
NIK1LK2 
migrated is indicated to the right of the 
right panel. The molecular masses of the marker proteins are indicated in kilodaltons 
(kDa) to the left of both panels. 
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Legend for supplementary Fig. S1. Analysis of the levels of expression and degrees of 
activation of pro-CLS-, pro-LS- and pro-S-mat
WT
 variants. Medium samples of 
COS-1 cells transfected with 4.8 g of pSecTag2/HygroB (Mock), 2.4 g of 
pSecTag2/HygroB and pSec-pro-CLS-mat
WT
 (CLS-WT), 2.4 g of pSecTag2/HygroB 
and pSec-pro-LS-mat
WT
 (LS-WT), 2.4 g of pSecTag2/HygroB and pSec-pro-S-matWT 















 (HAI-1 + S-WT), were subjected to reducing 
SDS-PAGE. After Western transfer, the blot was probed with Spr992 (upper panel) or 
S-protein–HRP (bottom panel). In the upper panel, the positions to which pro-S-matWT 




 migrated are 









migrated are indicated. The molecular 
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